Biodexa Pharmaceuticals (BDRX) Interest & Investment Income (2016 - 2024)

Biodexa Pharmaceuticals has reported Interest & Investment Income for 5 years, with the latest figure at $1.1 million in Q4 2024.

• Quarterly Interest & Investment Income changed N/A year-over-year to $1.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $3.1 million, down 27.62% from the prior year.
• Interest & Investment Income grew to $1.1 million in Q4 2024 per BDRX's latest filing, from $473863.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $1.1 million in Q4 2024 and troughed at $473863.0 in Q4 2022.
• A 3-year average of $672172.4 and a median of $639714.4 in 2020 frame the typical range for Interest & Investment Income.
• The widest YoY moves for Interest & Investment Income: up 52072.06% in 2020, down 52072.06% in 2020.
• Over 3 years, Interest & Investment Income stood at $670789.1 in 2020, then slipped by 29.36% to $473863.0 in 2022, then surged by 127.25% to $1.1 million in 2024.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $1.1 million, $473863.0, and $499637.3 for Q4 2024, Q4 2022, and Q3 2022 respectively.